Novo Nordisk sues Eli Lilly under Lanham Act over 2-year-old GLP-1 ad claims
Novo Nordisk alleges Eli Lilly’s comparative advertising for Zepbound relies on outdated clinical data, violating the Lanham Act. The case could redefine how quickly pharma competitors must update ad claims when new drug formulations enter the market.